Osteoarthritis Progression And Sensory Pathway Alterations

骨关节炎进展和感觉通路改变

基本信息

  • 批准号:
    8480989
  • 负责人:
  • 金额:
    $ 48.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-05-01 至 2018-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Osteoarthritis (OA) pain represents an enormous health burden. Patients describe different types of pain over the course of the disease, including pain with mechanical characteristics, neuropathic elements, and intermittent spontaneous pain. Signs of somatosensory disturbances such as mechanical allodynia, loss of proprioception, and vibratory deficits have been reported. Specialized sensory neurons mediate different sensations, including touch, proprioception, vibration, and different types of noxious stimuli. Therefore, we propose that "pain" in OA is more than merely a state where nociceptive neurons in the joint are activated, but rather involves widespread changes in sensory neurons, both in specialized subsets of nociceptive neurons and in non-nociceptive A¿ fibers. Our overall goal is to identify these changes in subsets of neurons in the course of progressive OA. We will use a validated murine model, destabilization of the medial meniscus (DMM) that captures the long-term progression of OA. In this model, pain-dependent behaviors change over time, with knee hyperalgesia and mechanical allodynia presenting early on, while symptoms of ongoing pain are not apparent until 8-16 weeks post DMM. This provides a unique opportunity to longitudinally assess neuronal properties. Our strategy will include three different approaches: (1) To define changes in specific subsets of sensory neurons in dorsal root ganglia (DRG) and joints in the course of knee OA - Subsets of sensory neurons in the joint and innervating DRG, L2-L5, will be documented throughout the progression of disease, through retrograde labeling and immunohistochemistry. Specifically, we will describe the number and location of peptidergic and non-peptidergic C-fibers, of non-nociceptive A¿-fibers, and their expression of markers including CCR2 and Nav1.8. We will validate our findings in a unique human joint tissue bank including patients with meniscal pathology, early and advanced stages of knee OA; (2) To characterize physiological properties of subsets of sensory neurons during initiation and maintenance of OA pain- We will analyse activity of individual subsets of A and C-fibers through electrophysiological recordings on intact DRG, L3/L4, and determine spontaneous activity as well as responses to stimuli including MCP-1, capsaicin, and ATP. We will also employ novel Pirt-GCaMP3 mice to image intracellular Ca2+ in sensory neurons in vivo in response to natural sensory stimuli, including mechanical stimulation applied to the knee; (3) To study the effect of selectively silencing subsets of neurons on different OA pain behaviors - We will test the effect of a selective ¿-opioid receptor on pain-dependent behaviors. We will also employ novel DREADD technology to transiently silence all sensory DRG neurons (using the pan-DRG Advillin promoter) or a subset of nociceptors (using Nav1.8 promoter). The proposal combines neuroanatomical techniques, electrophysiological measurements, in vivo imaging, and state-of-the-art approaches to reversibly silence neurons in order to evaluate changes in populations of sensory neurons that contribute to symptoms in a translational OA model.
描述(由申请人提供):骨关节炎(OA)疼痛是一个巨大的健康负担。患者在疾病过程中描述了不同类型的疼痛,包括具有机械特征的疼痛、神经病理因素和间歇性自发性疼痛。躯体感觉障碍的迹象,如机械性痛觉异常、本体感觉丧失和振动障碍已有报道。专门的感觉神经元调节不同的感觉,包括触摸、本体感觉、振动和不同类型的伤害性刺激。因此,我们认为,骨性关节炎的“痛”不仅仅是关节内伤害性神经元被激活的一种状态,而是涉及到伤害性神经元的特殊亚群和非伤害性A纤维中的感觉神经元的广泛变化。我们的总体目标是确定进行性骨性关节炎过程中神经元亚群的这些变化。我们将使用一个经过验证的小鼠模型,内侧半月板失稳(DMM),它捕捉到了OA的长期进展。在这个模型中,疼痛依赖行为随着时间的推移而改变,早期出现膝关节痛觉过敏和机械性超敏,而持续疼痛的症状直到DMM后8-16周才明显。这为纵向评估神经元特性提供了一个独特的机会。我们的策略将包括三种不同的方法:(1)通过逆行标记和免疫组织化学方法,确定膝关节炎过程中背根神经节(DRG)和关节中特定感觉神经元亚群的变化-关节和支配DRG的L2-L5感觉神经元亚群将被记录下来。具体地说,我们将描述肽能和非肽能C纤维、非伤害性A?纤维的数量和位置,以及包括CCR2和Nav1.8在内的标记的表达。我们将在一个独特的人类关节组织库中验证我们的发现,其中包括半月板病理患者、膝骨性关节炎的早期和晚期;(2)为了表征OA疼痛起始和维持期间感觉神经元亚群的生理特性-我们将通过电生理学分析A和C纤维的单个亚群的活性 在完整的背根节、L3/L4上记录,并测定自发活动以及对包括MCP-1、辣椒素和ATP在内的刺激的反应。我们还将利用新型Pirt-GCaMP3小鼠来对自然感觉刺激(包括膝盖上的机械刺激)做出反应时体内感觉神经元细胞内钙离子的变化进行成像;(3)研究选择性沉默神经元亚群对不同OA疼痛行为的影响--我们将测试选择性阿片受体对疼痛依赖行为的影响。我们还将使用新的DREADD技术来瞬时沉默所有感觉性DRG神经元(使用PAN-DRG Advilin启动子)或部分伤害性感受器(使用Nav1.8启动子)。该提案结合了神经解剖学技术、电生理测量、活体成像和最先进的可逆性沉默神经元的方法,以评估在翻译的OA模型中导致症状的感觉神经元群体的变化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD J MILLER其他文献

RICHARD J MILLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD J MILLER', 18)}}的其他基金

Neurobiology Core C
神经生物学核心 C
  • 批准号:
    10488613
  • 财政年份:
    2021
  • 资助金额:
    $ 48.32万
  • 项目类别:
Neurobiology Core C
神经生物学核心 C
  • 批准号:
    10676993
  • 财政年份:
    2021
  • 资助金额:
    $ 48.32万
  • 项目类别:
Osteoarthritis Progression And Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
  • 批准号:
    10169854
  • 财政年份:
    2020
  • 资助金额:
    $ 48.32万
  • 项目类别:
Small molecule CXCR4 modulators as molecular probes for studying AML
小分子 CXCR4 调节剂作为研究 AML 的分子探针
  • 批准号:
    9099791
  • 财政年份:
    2015
  • 资助金额:
    $ 48.32万
  • 项目类别:
Osteoarthritis Progression and Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
  • 批准号:
    8829147
  • 财政年份:
    2013
  • 资助金额:
    $ 48.32万
  • 项目类别:
Osteoarthritis Progression and Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
  • 批准号:
    9053984
  • 财政年份:
    2013
  • 资助金额:
    $ 48.32万
  • 项目类别:
Osteoarthritis Progression And Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
  • 批准号:
    9757504
  • 财政年份:
    2013
  • 资助金额:
    $ 48.32万
  • 项目类别:
Osteoarthritis Progression and Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
  • 批准号:
    8655517
  • 财政年份:
    2013
  • 资助金额:
    $ 48.32万
  • 项目类别:
Osteoarthritis Progression And Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
  • 批准号:
    10380166
  • 财政年份:
    2013
  • 资助金额:
    $ 48.32万
  • 项目类别:
Osteoarthritis Progression And Sensory Pathway Alterations
骨关节炎进展和感觉通路改变
  • 批准号:
    10626714
  • 财政年份:
    2013
  • 资助金额:
    $ 48.32万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 48.32万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 48.32万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 48.32万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 48.32万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 48.32万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 48.32万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 48.32万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 48.32万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 48.32万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 48.32万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了